DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

VistaGen Therapeutics Receives FDA Clearance Of IND For Phase 2 Clinical Study Of AV-101 As Potential Treatment Of Dyskinesia in Parkinson's Disease Patients

Benzinga · 01/30/2020 13:30